Regular readers will remember that Vertex has taken a commanding lead in the race with Schering -- to bring the next generation of Hep C drugs to market in the United States. This news, this morning, extends that lead. A Phase IIa trial, conducted by Vertex, has shown strong interim results.
When it rains, lately, in New Jersey -- in Kenilworth -- it pours.
Showing posts with label Telapravir v. Boceprevir Schering Plough Hep C Phase II Phase III Vertex Johnson and Johnson Hepititis C dosing chemical complications August 1 2008. Show all posts
Showing posts with label Telapravir v. Boceprevir Schering Plough Hep C Phase II Phase III Vertex Johnson and Johnson Hepititis C dosing chemical complications August 1 2008. Show all posts
Friday, August 1, 2008
Meanwhile, Vertex's Hep C Drug Candidate, Telapravir, keeps rollin' toward FDA Approvability. . . .
Subscribe to:
Posts (Atom)
